Total revenue for 2025 is estimated to be $672 million to $674 million, which exceeds the top end of the guidance range, and represents approximately 20% growth versus 2024. Crysvita revenue for 2025 is estimated to be $480 million to $482 million, which exceeds the top end of the guidance range, and represents approximately 17% growth versus 2024. Dojolvi revenue for 2025 is estimated to be $95 million to $97 million, at the midpoint of the guidance range, and represents approximately 9% growth versus 2024.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- Ultragenyx price target lowered to $50 from $55 at Morgan Stanley
- Ultragenyx: Trial Setback Creates Buying Opportunity as Diversified Pipeline and Commercial Base Support $60 Target
- Ultragenyx price target lowered to $60 from $80 at H.C. Wainwright
- Ultragenyx price target lowered to $52 from $64 at Guggenheim
- Ultragenyx price target lowered to $58 from $72 at BofA